{"uri": "eng-9418889", "concepts": [{"uri": "http://en.wikipedia.org/wiki/Monoclonal_antibody", "type": "wiki", "score": 100, "label": {"eng": "Monoclonal antibody"}}, {"uri": "http://en.wikipedia.org/wiki/Pre-exposure_prophylaxis", "type": "wiki", "score": 100, "label": {"eng": "Pre-exposure prophylaxis"}}, {"uri": "http://en.wikipedia.org/wiki/Food_and_Drug_Administration", "type": "wiki", "score": 96, "label": {"eng": "Food and Drug Administration"}}, {"uri": "http://en.wikipedia.org/wiki/COVID-19_vaccine", "type": "wiki", "score": 93, "label": {"eng": "COVID-19 vaccine"}}, {"uri": "http://en.wikipedia.org/wiki/Coronavirus", "type": "wiki", "score": 93, "label": {"eng": "Coronavirus"}}, {"uri": "http://en.wikipedia.org/wiki/Immunodeficiency", "type": "wiki", "score": 93, "label": {"eng": "Immunodeficiency"}}, {"uri": "http://en.wikipedia.org/wiki/Chief_executive_officer", "type": "wiki", "score": 93, "label": {"eng": "Chief executive officer"}}, {"uri": "http://en.wikipedia.org/wiki/Virus", "type": "wiki", "score": 89, "label": {"eng": "Virus"}}, {"uri": "http://en.wikipedia.org/wiki/Clinical_trial", "type": "wiki", "score": 89, "label": {"eng": "Clinical trial"}}, {"uri": "http://en.wikipedia.org/wiki/Antibody", "type": "wiki", "score": 86, "label": {"eng": "Antibody"}}, {"uri": "http://en.wikipedia.org/wiki/Immune_response", "type": "wiki", "score": 84, "label": {"eng": "Immune response"}}, {"uri": "http://en.wikipedia.org/wiki/SARS-CoV-2", "type": "wiki", "score": 82, "label": {"eng": "SARS-CoV-2"}}, {"uri": "http://en.wikipedia.org/wiki/COVID-19", "type": "wiki", "score": 82, "label": {"eng": "COVID-19"}}, {"uri": "http://en.wikipedia.org/wiki/Titer", "type": "wiki", "score": 82, "label": {"eng": "Titer"}}, {"uri": "http://en.wikipedia.org/wiki/Infusion", "type": "wiki", "score": 82, "label": {"eng": "Infusion"}}, {"uri": "http://en.wikipedia.org/wiki/Efficacy", "type": "wiki", "score": 82, "label": {"eng": "Efficacy"}}, {"uri": "http://en.wikipedia.org/wiki/Cohort_study", "type": "wiki", "score": 82, "label": {"eng": "Cohort study"}}, {"uri": "http://en.wikipedia.org/wiki/Anaphylaxis", "type": "wiki", "score": 82, "label": {"eng": "Anaphylaxis"}}, {"uri": "http://en.wikipedia.org/wiki/Tumors_of_the_hematopoietic_and_lymphoid_tissues", "type": "wiki", "score": 82, "label": {"eng": "Tumors of the hematopoietic and lymphoid tissues"}}, {"uri": "http://en.wikipedia.org/wiki/Hypersensitivity", "type": "wiki", "score": 82, "label": {"eng": "Hypersensitivity"}}, {"uri": "http://en.wikipedia.org/wiki/Duke_University_School_of_Medicine", "type": "org", "score": 53, "label": {"eng": "Duke University School of Medicine"}}], "eventDate": "2024-03-22", "totalArticleCount": 5, "title": {"eng": "Invivyd's monoclonal antibody receives FDA emergency use authorization By Investing.com"}, "summary": {"eng": "WALTHAM, Mass. - Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company, announced today the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for PEMGARDA\u2122 (pemivibart), a monoclonal antibody (mAb) for pre-exposure prophylaxis (PrEP) of COVID-19.\n\nThis authorization targets certain adults and adolescents with moderate-to-severe immune compromise who are not expected to mount an adequate immune response to COVID-19 vaccination.\n\nPEMGARDA is the first PrEP m"}, "location": null, "categories": [{"uri": "dmoz/Health/Specific_Substances/Tobacco", "label": "dmoz/Health/Specific Substances/Tobacco", "wgt": 100}, {"uri": "dmoz/Shopping/Health/Conditions_and_Diseases", "label": "dmoz/Shopping/Health/Conditions and Diseases", "wgt": 100}, {"uri": "dmoz/Health/Conditions_and_Diseases/Allergies", "label": "dmoz/Health/Conditions and Diseases/Allergies", "wgt": 100}, {"uri": "news/Health", "label": "news/Health", "wgt": 84}], "articleCounts": {"eng": 5}, "sentiment": 0.3960784313725489, "wgt": 448761600, "relevance": 1}